Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
December 01, 2020 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
November 25, 2020 09:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
November 13, 2020 07:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights
November 05, 2020 16:01 ET
|
Oyster Point Pharma, Inc.
OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease Remains on Track for Q4 2020OC-01 Investigational New Drug (IND)...
Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020
October 29, 2020 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth
October 08, 2020 16:01 ET
|
Oyster Point Pharma, Inc.
Ali Behbahani, M.D. takes on role of Chairperson of the Board Michael G. Atieh joins the Board of Directors as Chairperson of the Audit Committee PRINCETON, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE)...
Oyster Point Pharma to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
September 11, 2020 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
August 05, 2020 07:00 ET
|
Oyster Point Pharma, Inc.
OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020Cash and Cash Equivalents of $226.7 million as...
Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020
July 31, 2020 16:01 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 19, 2020 18:08 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...